Clinical Trials Logo
  1. Home
  2. Graft Versus Host Disease
  3. NCT03438643

Dynamic of Immunocompetent Populations in Patients Treated With Extracorporeal Photopheresis in Chronic Graft Versus Host Disease — IMMUNO-PEC  

Graft Versus Host Disease Clinical Trial

Official title:
Dynamic of Immunocompetent Populations in Patients Treated With Extracorporeal Photopheresis in Chronic Graft Versus Host Disease

Clinical Trial Summary

Extracorporeal photopheresis (ECP) is a cellular therapy indicated in the treatment of chronic GVHD (cGVHD). In this study protocol, patients suffering from inaugural cGVHD will be treated with the association of ECP and corticosteroid treatment. Treatment will start by an induction stage with 2 sessions of ECP per week until the 10th week followed by a maintenance stage including one session every other week until the 22th week. The objective of this study is to highlight the immunological mechanism of extracorporeal photopheresis treatment. Indeed, ECP is based on an immunomodulatory immunological effect and despite several hypotheses highlighted by different teams; clear mechanisms still need to be defined. This French multicenter study realize an immunological follow-up before and during treatment to elucidate the impact of ECP on immune system of responder patient.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03438643
Study type Observational
Source University Hospital, Lille
Contact Ibrahim YAKOU BAGHA, MD,PhD
Phone 320 444 176
Email ibrahim.yakoubagha@chru-lille.fr
Status Recruiting
Phase
Start date May 7, 2018
Completion date November 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03357159 - Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Recruiting NCT01385124 - Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation Phase 1/Phase 2
Withdrawn NCT01616680 - Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease Phase 2
Recruiting NCT01810926 - T&B Depletion Non Malignant Phase 2
Completed NCT01379209 - Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Phase 1/Phase 2
Completed NCT01233921 - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer N/A
Recruiting NCT00986557 - T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant Phase 2
Enrolling by invitation NCT00972660 - Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease Phase 2
Terminated NCT00555048 - Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Phase 1/Phase 2
Terminated NCT00373815 - Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease Phase 1
Terminated NCT00608517 - Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil N/A
Completed NCT00056875 - Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants Phase 1/Phase 2
Recruiting NCT05808985 - Intestinal Microbiome-based Research for the Prevention of Acute GVHD Phase 2
Completed NCT00813618 - Study of MEDI 507 in the Treatment of Pediatric Patients Phase 1
Completed NCT00003398 - Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Phase 4
Terminated NCT00005641 - Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation Phase 2
Completed NCT02663622 - Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) Phase 2
Completed NCT00577278 - A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan Phase 2